Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults

References

• American Cancer Society (ACS). Key statistics for childhood leukemia. ACS. cited 2021 Jul 28 at https://www.cancer.org/cancer/leukemia-in-children/about/key-statistics.html
   Google Scholar
• Sun W, Malvar J, Sposto R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32:2316–2325.
   PubMed Web of Science ®Google Scholar
• Martin A, Morgan E, Hijiya N. Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments. Paediatr Drugs. 2012;14(6):377–387.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Schrappe M, Bernardo M, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;4:2.
   Google Scholar
• Scalo F, Rascati KL. Trends and issues in oncology costs. Expert Rev. Pharmacoecon. Outcomes Res. 2014;14:35–44.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 2015;121:3372–3379.
   PubMed Web of Science ®Google Scholar
• Pui H, Evans E. A 50‐year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50:185–196.
   PubMed Web of Science ®Google Scholar
• Stephen PH, Elizabeth AR. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136:15.
   Google Scholar
• Kaul S, Korgenski EK, Ying J, et al. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer Med. 2016;5(2):221–229.
   PubMed Web of Science ®Google Scholar
• Rasche M, Steidel E, Zimmermann M, et al. Second relapse of pediatric patients with acute myeloid leukemia: a report on current treatment strategies and outcome of the AML-BFM study group. Cancers (Basel). 2021;13(4):789.
   PubMedGoogle Scholar
• Hoffman AE, Schoonmade LJ, Kaspers GJL. Pediatric relapsed acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 2021;21(1):45–52.
   PubMed Web of Science ®Google Scholar
• Forsythe A, Sandman KE. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med. 2021;12:245–255.
   PubMed Web of Science ®Google Scholar
• Shemilt I, Mugford M, Byford S, et al. Chapter 15: incorporating economics evidence. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011. p. 449–80. Version 5.1.0 (cited March 2011). The Cochrane Collaboration. Accessed on 28 Jul 2021 at www.handbook.cochrane.org
   Google Scholar
• Russell HV, Panchal J, Vonville H, et al. Economic evaluation of pediatric cancer treatment: a systematic literature review. Pediatrics. 2013;131(1):e273–87.
   PubMedGoogle Scholar
• Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. York, UK: University of York; 2009.
   Google Scholar
• PRISMA Group: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;51:264–269.
   Google Scholar
• Craig D, Rice S. NHS economic evaluation database handbook: centre for reviews and dissemination. York, UK: University of York; 2007.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Eff Resour Alloc. 2013;11(1):6.
   PubMedGoogle Scholar
• Fung A, Horton S, Zabih V, et al. Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review. BMJ Glob Health. 2019;4:e001825.
   PubMed Web of Science ®Google Scholar
• The Professional Society for Health Economics and Outcomes Research (ISPOR). cited 2021 Nov 10 th. https://www.ispor.org/home
   Google Scholar
• The World Bank Indicators. Official exchange rate (LCU per US$, period average). World Bank Group. cited 2020 Aug 28th. Available at: https://data.worldbank.org/indicator/PA.NUS.FCRF?view=chart
   Google Scholar
• The World Bank Indicators. GDP deflator (base year varies by country). world bank group. cited Aug 28, 2020. Available at 2020 Aug 28: https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS
   Google Scholar
• Lin YF, Lairson DR, Chan W, et al. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010;16(9):1272–1281.
   PubMed Web of Science ®Google Scholar
• Maser B, Pelland-Marcotte M-C, Alexander S, et al. Levofloxacin prophylaxis in hospitalized children with leukemia: a cost-utility analysis. Pediatr Blood Cancer. 2020;67:e28643.
   PubMedGoogle Scholar
• Lin JK, Lerman BJ, Barnes JI, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192–3202. 10.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161–1168. 1.
   PubMed Web of Science ®Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719–726. 1.
   PubMedGoogle Scholar
• Santasusana R, Saldaña A, García-Muñoz N, et al. Cost-effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in children and young adults in Spain. Clinicoecon Outcomes Res. 2020;12:253–264.
   PubMedGoogle Scholar
• Thielen FW, van Dongen-leunis A, Arons AMM, et al. Cost-effectiveness of anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. Eur J Haematol. 2020;105(2):203–215.
   PubMed Web of Science ®Google Scholar
• Furzer J, Sumit G, Paul C, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol. 2020;6(3):393–401.
   PubMed Web of Science ®Google Scholar
• Yang H, Hao Y, Qi CZ, et al. Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a U.S. hospital’s perspective. J Manag Care Spec Pharm. 2020;26(8):971–980.
   PubMed Web of Science ®Google Scholar
• Schulthess D, Gassull D, Makady A, et al. Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants. BMJ Evid Based Med. 2021;26(3):98–102.
   PubMedGoogle Scholar
• Wakase S, Teshima T, Zhang J, et al. Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan. Transplant Cell Ther. 2021;27(3):241.e1–241.e11.
   PubMedGoogle Scholar
• Moradi-Lakeh M, Yaghoubi M, Seitz P, et al. Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-cell lymphoma (DLBCL) in Switzerland. Adv Ther. 2021;38(6):3427–3443.
   PubMed Web of Science ®Google Scholar
• Fiorenza S, Ritchie DS, Ramsey SD, et al. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55:1706–1715.
   PubMed Web of Science ®Google Scholar
• Pepper MS, Alessandrini M, Pope A, et al. Cell and gene therapies at the forefront of innovative medical care: implications for South Africa. S Afr Med J. 2018;109(1):20–22. 13.
   PubMedGoogle Scholar
• Cornetta K, Patel K, Wanjiku CM, et al. Equitable access to gene therapy: a call to action for the American society of gene and cell therapy. Mol Ther. 2018;26(12):2715–2716. 5.
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Kymriah (tisagenlecleucel). What are the risks associated with Kymriah? cited 2022 Jan 20th. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah
   Google Scholar
• Gye A, Goodall S, De Abreu L. A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients. Value Health. 2022;25(1):47–58.
   PubMedGoogle Scholar
• Petrou P. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):529–536.
   PubMed Web of Science ®Google Scholar
• Heine R, Thielen FW, Koopmanschap M, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. Hemasphere. 2021;5(2):e524.
   PubMed Web of Science ®Google Scholar
• Pechlivanoglou P, Luu L, Li Q, et al. Blinatumomab is cost-effective compared to standard chemotherapy for children with high-risk relapses of acute lymphoblastic leukemia: a cost-effectiveness analysis using population-based healthcare data. Blood. 2021;38(1):565.
   Google Scholar
• Hoffman A, Schoonmade L, Kaspers G. Pediatric relapsed acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 2021;21(1):45–52.
   PubMed Web of Science ®Google Scholar
• Mamolo C, Welch V, Walter RB, et al. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021;39(1):121–131.
   PubMedGoogle Scholar
• Jaime-Pérez JC, Heredia-Salazar AC, Cantú-Rodríguez OG, et al. Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico. Oncologist. 2015;20(4):386–392.
   PubMed Web of Science ®Google Scholar